CG
CGON.US CG Oncology, Inc. Common stock
- Market cap
- USD 6.65B
- P/E
- -
- P/B
- 6.33x
- ROE
- -26.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CGON.US undervalued?
Graham numberThe Graham number of CG Oncology, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CG Oncology, Inc. Common stock fundamental analysis
No fundamental analysis for CG Oncology, Inc. Common stock yet.
CG Oncology, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy i…
Full company profileCG Oncology, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CG Oncology, Inc. Common stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 10.4M | 191K | 204K | 1.14M | 4.04M | 5.13M |
| Gross Profit | 10.3M | 176K | -45.5M | -81.0M | -607K | -7.62M |
| Operating Income | -12.6M | -35.2M | -55.4M | -115M | -191M | -288M |
| EBITDA | -12.4M | -35.4M | -48.6M | -88.0M | -160M | -258M |
| Net Income | -12.8M | -35.4M | -48.6M | -88.0M | -161M | -262M |
| EPS | -0.19 | -0.53 | -0.73 | -1.41 | -2.08 | -2.94 |
| Balance Sheet | ||||||
| Total Assets | 58.7M | 148M | 199M | 755M | 792M | 1.05B |
| Total Liabilities | 18.4M | 22.6M | 14.5M | 21.4M | 39.0M | 55.7M |
| Shareholders' Equity | 40.3M | 125M | 185M | 733M | 753M | 991M |
| Cash & Short-term Investments | 53.6M | 143M | 188M | 742M | 742M | 984M |
| Total Debt | 15.1M | 15.9M | 1.03M | 238K | 7.02M | 9.24M |
| Cash Flow | ||||||
| Operating Cash Flow | -13.7M | -29.8M | -45.7M | -78.7M | -132M | -201M |
| Capital Expenditure | 97.0K | 14.0K | 0.00 | 234K | 134K | 2.52M |
| Free Cash Flow | -13.8M | -29.8M | -45.7M | -78.9M | -132M | -204M |
| Ratios | ||||||
| ROE | -31.9% | -28.3% | -26.3% | -12.0% | -21.4% | -26.4% |
| ROA | -21.9% | -24.0% | -24.4% | -11.7% | -20.3% | -25.0% |
| Net Profit Margin | -124.0% | -18,556.5% | -23,827.0% | -7,729.5% | -3,985.0% | -5,102.7% |
| Debt to Equity | 0.38x | 0.13x | 0.01x | 0.00x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CG Oncology, Inc. Common stock dividends
CG Oncology, Inc. Common stock has not paid dividends in the last 5 fiscal years.
Who owns CG Oncology, Inc. Common stock
- Insiders 0.23%
- Institutions 99.77%
- Public & others 0.00%
- Shares outstanding 89.3M
- Free float 69.0M
Top funds holding CGON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.56M | 2.89% | +7.14% | Sep 2026 |
| Vanguard Health Care Inv | 2.54M | 2.86% | -11.24% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 2.41M | 2.72% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.87M | 2.11% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.79M | 2.02% | +3.96% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.65M | 1.87% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.00M | 1.13% | +102.61% | Sep 2026 |
| T. Rowe Price New Horizons | 837K | 0.94% | -19.23% | Sep 2026 |
| Fidelity Small Cap Index | 808K | 0.91% | +0.15% | Aug 2026 |
| Fidelity Small Cap Growth | 797K | 0.90% | 0.00% | Aug 2026 |
| T. Rowe Price Mid-Cap Growth | 744K | 0.84% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 692K | 0.78% | -0.38% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 562K | 0.63% | -21.23% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 558K | 0.63% | +83.28% | Sep 2026 |
| JNL/T. Rowe Price Capital Appreciation A | 558K | 0.63% | -4.82% | Sep 2026 |
| American Century Small Cap Growth Inv | 554K | 0.63% | 0.00% | Sep 2026 |
| Worldwide Healthcare Ord | 550K | 0.62% | 0.00% | Jul 2026 |
| Strategic Advisers Fidelity US TtlStk | 517K | 0.58% | +23.82% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 480K | 0.54% | 0.00% | Aug 2026 |
| Fidelity Select Health Care | 460K | 0.52% | 0.00% | Aug 2026 |
Top institutions holding CGON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RTW INVESTMENTS, LLC | 8.51M | 9.61% | +21.90% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 6.62M | 7.46% | -1.54% | Jun 2026 |
| Decheng Capital LLC | 6.37M | 7.19% | 0.00% | Jun 2026 |
| BlackRock Inc | 6.26M | 7.06% | +23.54% | Jun 2026 |
| Wellington Management Company LLP | 5.32M | 6.01% | -0.87% | Jun 2026 |
| FMR Inc | 4.16M | 4.69% | +10.54% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.81M | 4.29% | +4.16% | Jun 2026 |
| TCG Crossover Management, LLC | 3.67M | 4.14% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.47M | 3.91% | +11.96% | Jun 2026 |
| State Street Corp | 3.44M | 3.88% | +29.86% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.32M | 3.74% | +9.33% | Jun 2026 |
| Foresite Capital Management VI LLC | 2.37M | 2.67% | +6.67% | Jun 2026 |
| Geode Capital Management, LLC | 2.15M | 2.43% | +34.84% | Jun 2026 |
| Seven Fleet Capital Management LP | 1.89M | 2.13% | +24.49% | Jun 2026 |
| EcoR1 Capital, LLC | 1.49M | 1.69% | +35.60% | Jun 2026 |
| DV Trading LLC | 1.44M | 1.62% | 0.00% | Jun 2026 |
| Avidity Partners Management LP | 1.40M | 1.58% | +8.53% | Jun 2026 |
| AllianceBernstein L.P. | 1.37M | 1.55% | +6.52% | Jun 2026 |
| Franklin Templeton Inc | 1.31M | 1.48% | -12.88% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.18M | 1.33% | +126.27% | Jun 2026 |
CG Oncology, Inc. Common stock company profile
- Company name
- CG Oncology, Inc. Common stock
- Ticker
- CGON.US
- Exchange
- USA Stocks
- Listed since
- Jan 25, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Fiscal year end
- December
- Address
- 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
- Phone
- 949 409 3700
- Website
- cgoncology.com
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
CG Oncology, Inc. Common stock management
10- Mr. Arthur KuanPresident, Chairman & CEO · born 1991
- Mr. James M. DeToreChief Financial Officer · born 1965
- Mr. Joshua F. PattersonGeneral Counsel, Chief Compliance Officer & Secretary · born 1977
- Dr. Vijay Kasturi M.D.Chief Medical Officer · born 1968
- Mr. Swapnil Bhargava Ph.D.Chief Technical Officer
- Ms. Amy SteeleVice President of Finance & Administration
- Ms. Megan E. KnightVice President of Investor Relations
- Ms. Sarah ConnorsVice President of Communications & Patient Advocacy
- Mr. Bing KungVice President of Corporate Development
- Ms. Isabel KalofonosChief Commercial Officer · born 1971